Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Next Steps When Treating mRCC Patients Who Receive I-O In The Front Line Space. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Author: Editor
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses IO-TKI Combinations In Renal Cell Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses How To Treat mRCC After Combination I-O In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses Single Agent TKIs In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses Intermediate/Poor & Favorable Risk RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses KEYNOTE 426 Phase III Trial In Metastatic Renal Cell Carcinoma. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study In Pre-Metastatic Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor Inhibitors. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES Trial In mHSPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses The Outcomes Of KEYNOTE 426 Presented At GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses How To Treat mRCC After Combination I-O In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Intermediate/Poor And Favorable Risk RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Predictive Biomarkers In Selecting Patient Populations For I-O Treatment In RCC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd. Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.  In return for the license and future rights, Ohara will make a multi-part payment to Oncoceutics including upfront payments, milestone payments,…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Should Patients In The 1st Line Setting Should Receive A Single Agent TKI. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Aimwithimmunotherapy.org And The Various Resources The Site Provides For Patients And Physicians.
(WASHINGTON, March 12, 2019) — Yesterday, President Donald Trump released a fiscal year 2020 budget request that proposes a 12 percent cut to the U.S. Department of Health and Human Services (HHS). This includes a $4.716 billion (12.1%) cut to the National Institutes of Health (NIH), the nation’s largest funder of biomedical research, and a $750 million cut in funding to the Centers for Disease Control and Prevention (CDC). These agencies play a vital role in supporting much of the world’s hematology-related biomedical research and in supporting programs to prevent and control clotting, bleeding, and other hematologic disorders. 2019 American…
Wood LS, Hoffner B, Rubin K, Davies MJ, Tushla LA, Guild V, Guild SR. Background Immune checkpoint inhibitors (ICIs) have changed treatment options for many cancer patients. Educating HCPs, patients, caregivers is crucial to early identification of irAEs, ensuring prompt intervention and improved outcomes. Resources for oncology HCPs are scattered, including published articles, websites, and pharmaceutical materials. These resources are restricted to information from the package insert and limited in the scope of guidance provided. Methods Melanoma advance practice providers (APPs) collaborated with the AIM at Melanoma Foundation and Terranova Medica in 2016 to create the Melanoma Nurse Initiative, featuring…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Whats Next With Aimwithimmunotherapy.org. For More Info Visit: Aimwithimmunotherapy.org
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Benefits Of Aimwithimmunotherapy.org And The Various Resources It Provides For Patients And Physicians. For More Info Visit: Aimwithimmunotherapy.org
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Assessment & Education Regarding (irAEs). For More Info Visit: Aimwithimmunotherapy.org
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient support.
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-01 With a focus on integrating recent advances into improved care pathways, this on-demand webcast features a presentation on the latest treatment options, current guidelines, available cost data, and expert recommendations. © 2018 NACCME, an HMP Company
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02 This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies. © 2018 NACCME, an HMP Company
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-04 This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies in AML, including novel chemotherapy formulations, FLT3 inhibitors, and IDH inhibitors for informed pathway placement. © 2018 NACCME, an HMP Company
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-03 This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-class differences in the mechanisms of action, efficacy and safety, and indications of available and emerging PARP inhibitors for optimal ovarian cancer pathway integration. © 2018 NACCME, an HMP Company
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-05 This on-demand webcast examines recent clinical trial data for novel and emerging therapies, including doublet and triplet combinations for relapsed/refractory disease, and discusses how best to integrate recent therapeutic advances into clinical pathways. © 2018 NACCME, an HMP Company
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Checkmate 227 & Keynote 042 Potential Practice Changing Approaches. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Have Advances In NSCLC Extended To The Elderly. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses How To Participate In “Feel More Like You”. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses Benefits Of “Feel More Like You” Program. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses “Feel More Like You” Program. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Personalized Medicine In Pancreas Cancer. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Know Your Tumor Initiative. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Evolution Of Pancreatic Cancer Treatment. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Elaborating On Pancreas Cancer. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Whats New In AML Transplants. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Strategies To Treat AML. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org